biologic

waskyra

etuvetidigene autotemcel

Loss of exclusivityDecember 2037projected — 12-year biologic exclusivity estimate
CompanyFondazione Telethon Ets

Drug detail

Brand namewaskyra
Active ingredientetuvetidigene autotemcel
Strength1.9-11.4x10^6CD34+ CELLS/ML
Dosage formSolution
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

waskyra patent cliff — loss of exclusivity December 2037 | CliffBio